

DAFTAR PUSTAKA

1. World Health Organization (WHO). Breast cancer now most common form of cancer. 2021; Tersedia pada: <https://www.who.int>
2. Global Cancer Observatory (GCO). Indonesia Fact Sheet [Internet]. 2021. hal. 1. Tersedia pada: <https://gco.iarc.fr>
3. Indra. Sosialisasi Hari Kanker Sedunia dengan Guru SMA 1 Padang [Internet]. Dinas Kesehatan Provisni Sumatera Barat. 2020. Tersedia pada: <https://dinkes.sumbarprov.go.id/details/news/467>
4. Briani Sobri F. Terapi Sistemik Kanker Payudara dengan Reseptor Hormon Positif. In: Manajemen Terkini Kanker Payudara. edisi II 2. Sagung Seto; 2018. hal. 254.
5. Xu H, Jin F, Zhang X jie, Wang D qiu, Yu S fen, Wang A ping. Adherence status to Adjuvant Endocrine Therapy in Chinese Women with Early Breast Cancer and its influencing factors: A cross-sectional survey. *Cancer Med.* 2020;9(11):3703–13.
6. Sisti JS, Bernstein JL, Lynch CF, Reiner AS, Mellemkjaer L, Brooks JD, et al. Reproductive factors, tumor estrogen receptor status and contralateral breast cancer risk: results from the WECARE study. *Springerplus.* 2015;4(1):1–11.
7. World Health Organization (WHO). Breast Cancer [Internet]. 2021. Tersedia pada: <https://www.who.int>
8. Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KA, et al. Adjuvant endocrine therapy for women with hormone receptor–positive breast cancer: ASCO clinical practice guideline focused update. *J Clin Oncol.* 2019;37(5):423–38.
9. Khambri D. Peran terapi hormonal pada kanker payudara. *Maj Kedokt Andalas.* 2015;38:64–73.
10. Ricci-Cabello I, Vásquez-Mejía A, Canelo-Aybar C, Niño De Guzman E, Pérez-Bracchiglione J, Rabassa M, et al. Adherence to breast cancer guidelines is associated with better survival outcomes: A systematic review and meta-analysis of observational studies in EU countries. *BMC Health Serv Res.* 2020;20(1):1–12.

11. Baum M, Brinkley DM, Dosset JA, McPherson K, Jackson IM, Rubens RD, et al. Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. *Br J Cancer*. 1988;57(6):608–11.
12. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. *Lancet* [Internet]. 2013;381(9869):805–16. Tersedia pada:
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3596060/?report=reader>
13. Bradley R, Burrett J, Clarke M, Davies C, Duane F, Evans V, et al. Aromatase inhibitors versus tamoxifen in early breast cancer: Patient-level meta-analysis of the randomised trials. *Lancet* [Internet]. 2015;386(10001):1341–52. Tersedia pada:
<https://pubmed.ncbi.nlm.nih.gov/26211827/>
14. Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai WY, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. *J Clin Oncol*. 2010;28(27):4120–8.
15. Budiman A, Khambri D, Bachtiar H. Affecting's factor to medication adherence of patient with Tamoxifen after surgery. *J FK Univ Andalas*. 2013;2(1):20–4.
16. Halilintar VD, Nadjib M, Andalusia LR. Medication Adherence of Tamoxifen to Breast Cancer Patients and the Affecting's Factors in Dharmais Cancer Hospital Jakarta. *J Medicoeticolegal dan Manaj Rumah Sakit*. 2020;9(2):100–9.
17. Farias AJ, Hansen RN, Zeliadt SB, Ornelas I, Li C, Thompson B. The association between out-of-pocket costs and adherence to adjuvant endocrine therapy among newly diagnosed breast cancer patients. *HHS Public Access*. 2018;
18. Winn AN, Dusetzina SB. The association between trajectories of endocrine therapy adherence and mortality among women with breast cancer. *Pharmacoepidemiol Drug Saf*. 2016;25(8):953–9.

19. Kaleva V. Adherence to medication. *Pediatriya*. 2015;55(2):68–9.
20. Muliawan BT. Pelayanan konseling akan meningkatkan kepatuhan pasien pada terapi obat. *binfar depkes* [Internet]. 2008; Tersedia pada: http://www.binfar.depkes.go.id/def_menu.php
21. Wahyudi I. Padang resmi berstatus PPKM level III. *antaranews* [Internet]. 2022; Tersedia pada: <https://www.antaranews.com/berita/2706269/padang-resmi-berstatus-ppkm-level-iii>
22. Mujamil, Sety LOM, Zainuddin A, Kusnan A. Analisis Faktor Yang Berhubungan Terkait Kepatuhan Minum Obat Pasien Tuberkulosis Paru BTA+ di Masa Pandemi Covid 19 di Puskesmas Wilayah Kota Kendari. *J Nurs Updat* [Internet]. 2021;12(No.2). Tersedia pada: <https://stikes-nhm.e-journal.id/NU/article/view/348>
23. Soewoto W. Breast cancer patients therapeutic adherence during the COVID-19 pandemic in Indonesia. *J Clin Oncol* [Internet]. 1 Oktober 2021;39(28):89–89. Tersedia pada: https://ascopubs.org/doi/abs/10.1200/JCO.2020.39.28_suppl.89
24. Watson FR, Glass RL. Breast cancer staging systems. Vol. 4, *Journal of Surgical Oncology*. 2017. 369–375 hal.
25. Khanna S, Kim KN, Qureshi MM, Agarwal A, Parikh D, Ko NY, et al. Impact of patient demographics, tumor characteristics, and treatment type on treatment delay throughout breast cancer care at a diverse academic medical center. *Int J Womens Health*. 2017;9:887–96.
26. briani sobri F, Azhar Y. *Manajemen Operatif Kanker Payudara*. In: *Manajemen Terkini Kanker Payudara*. edisi II 2. Sagung Seto; 2018. hal. 254.
27. Fadhil M, Harahap WA, Rusnita D. Hasil Pengobatan Adjuvan Tamoxifen pada Pasien. *cdkjournal*. 2019;46(12):748–52.
28. Adherence to Long-Term Therapies. *World Heal Organ* [Internet]. 2003;3. Tersedia pada: https://www.who.int/chp/knowledge/publications/adherence_report/en/
29. The U.S. Food and Drug Administration (FDA). Are You Taking Medication as Prescribed [Internet]. 2009 [dikutip 21 Maret 2021]. Tersedia pada:

<https://www.fda.gov/consumers/consumer-updates/are-you-taking-medication-prescribed>

30. The American Medical Association. Medication Adherence Improve Patient Outcomes and Reduce Costs. 2015 [dikutip 21 Maret 2021]; Tersedia pada: <https://edhub.ama-assn.org/steps-forward/module/2702595>
31. InfoPOM. Kepatuhan pasien. 2006;7(5):1–12.
32. Lailatushifah SNF. Kepatuhan Pasien yang Menderita Penyakit Kronis Dalam Mengonsumsi Obat Harian. Fak Psikol Univ Mercu Buana Yogyakarta [Internet]. 2012;1–9. Tersedia pada: <http://fpsi.mercubuana-yogya.ac.id>
33. Rosyida et al. Kepatuhan Pasien pada Penggunaan Obat Antidiabetes dengan Meode Pill-Count dan MMAS-8 di Puskesmas Kedurus Surabaya. J Farm Komunitas. 2015;2(2):36–41.
34. Badan Pusat Statistik (BPS). Persentase Penduduk Miskin September 2021 turun menjadi 9,71 persen. 3 Juni 2022; Tersedia pada: <https://www.bps.go.id>
35. Hukum Online. Undang-Undang Nomor 20 Tahun 2003. 2020;1–31. Tersedia pada: <https://www.hukumonline.com>
36. JKN. Buku Panduan Jaminan Kesehatan Nasional. 2014;(April):3–4.
37. WHO. COVID-19 [Internet]. 2022. Tersedia pada: <https://covid19.who.int/region/searo/country/id>
38. corona.padang.go.id. Corona Padang [Internet]. 2022. Tersedia pada: <http://corona.padang.go.id>
39. McIntosh K. COVID-19: Epidemiology, virology, and prevention [Internet]. UpToDate. 2022. Tersedia pada: <https://www.uptodate.com>
40. World Health Organization (WHO). Maternal, Newborn, Child and Adolescent Health and Ageing [Internet]. 2022. Tersedia pada: [https://www.who.int/data/maternal-newborn-child-adolescent-ageing/indicator-explorer-new/mca/women-of-reproductive-age-\(15-49-years\)-population-\(thousands\)](https://www.who.int/data/maternal-newborn-child-adolescent-ageing/indicator-explorer-new/mca/women-of-reproductive-age-(15-49-years)-population-(thousands))
41. Trindade AJ, Ehrlich A, Kornbluth A, Ullman TA. Inflammatory bowel diseases. Pubmed [Internet]. Februari 2011;17(2):599–604. Tersedia pada:

<https://academic.oup.com/ibdjournal/article/17/2/599-604/4636158>

42. Hakim LN. Urgensi Revisi Undang-Undang tentang Kesejahteraan Lanjut Usia. *Aspir J Masal Sos.* 2020;11(1):43–55.
43. BPJS. Peserta [Internet]. 2020. Tersedia pada: <https://bpjs-kesehatan.go.id/bpjs/index.php/pages/detail/2014/11>
44. Azhar Y, Briani Sobri F, Prajoko YW. Subtipe Kanker Payudara Berdasarkan Klasifikasi Molekuler dan Manfaatnya Bagi Klinisi. In: *Manajemen Terkini Kanker Payudara. II 2018.* Sagung Seto; 2018. hal. 92–101.
45. Viktil KK, Blix HS, Moger TA, Reikyam A. Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems. *Br J Clin Pharmacol* [Internet]. Februari 2007;63(2):187–95. Tersedia pada: <https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2125.2006.02744.x>
46. Grover A, Oberoi M, Rehan HS, Gupta LK, Yadav M. Self-reported Morisky Eight-item Medication Adherence Scale for Statins Concords with the Pill Count Method and Correlates with Serum Lipid Profile Parameters and Serum HMGCoA Reductase Levels. *Cureus.* 2020;12(1):1–10.
47. Utomo ARH. Memahami proses karsinogenesis kanker payudara. In: briani sobri F, Azhar Y, Wibisana IG, Rachman A, editor. *Manajemen Terkini Kanker Payudara. II 2018.* Sagung Seto; 2018. hal. 36–54.
48. Sihombing M, Sapardin AN, Penelitian B, Ri KK. Faktor Risiko Tumor Payudara pada Perempuan Umur 25-65 tahun di Lima Kelurahan Kecamatan Bogor Tengah. *Kementerian Kesehat Republik Indones.* 2011;
49. Badan Pusat Statistik (BPS). Persentase Penduduk yang Memiliki Jaminan Kesehatan Menurut Provinsi dan Jenis Jaminan, 2021 [Internet]. Meta data Subdirektorat Statistik Kesehatan dan Perumahan. 2021. Tersedia pada: https://www.bps.go.id/indikator/indikator/view_data_pub/0000/api_pub/U/ROM3IMeGsxZ0czT2xFeEJsK0VWZz09/da_04/1
50. Zamrodah Y. Peran Ditjen Kesmas Daman Pndemi COVID 19 2020-2021. *2016;15(2):1–23.*
51. Ali EE, Cheung KL, Lee CP, Leow JL, Yap KY, Chew L. Prevalence and

- determinants of adherence to oral adjuvant endocrine therapy among breast cancer patients in Singapore. *Asia-Pacific J Oncol Nurs*. 2017;4(4):283–9.
52. Jiang H, Dong Y, Zong W, Zhang X jie, Xu H, Jin F. The relationship among psychosocial adaptation, medication adherence and quality of life in breast cancer women with adjuvant endocrine therapy. *BMC Womens Health* [Internet]. 2022;22(1):1–11. Tersedia pada: <https://doi.org/10.1186/s12905-022-01722-0>
53. Notoatmodjo S. *Metodologi penelitian kesehatan*. Jakarta: Rineka Cipta; 2010.
54. Peltzer K, Pengpid S. Socioeconomic factors in adherence to HIV therapy in low- and middle-income countries. *J Heal Popul Nutr*. 2013;31(2):150–70.
55. Pujasari A, Setyawan H, Udiyono. Faktor – Faktor Internal Ketidakpatuhan Pengobatan Hipertensi Di Puskesmas Kedungmundu Kota Semarang. *J Kesehat Masy* [Internet]. 2015;3(3):99–108. Tersedia pada: <http://www.tjyybjb.ac.cn/CN/article/downloadArticleFile.do?attachType=PDF&id=9987>
56. Guan WJ, Ni Z, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med*. 2020;
57. Fontein DBY, Nortier JWR, Liefers GJ, Putter H, Meershoek-Klein Kranenbarg E, van den Bosch J, et al. High non-compliance in the use of letrozole after 2.5years of extended adjuvant endocrine therapy. *Eur J Surg Oncol* [Internet]. Februari 2012;38(2):110–7. Tersedia pada: <https://linkinghub.elsevier.com/retrieve/pii/S0748798311006986>
58. Yussof I, Mohd Tahir NA, Hatah E, Mohamed Shah N. Factors influencing five-year adherence to adjuvant endocrine therapy in breast cancer patients: A systematic review. *The Breast* [Internet]. April 2022;62:22–35. Tersedia pada: <https://linkinghub.elsevier.com/retrieve/pii/S0960977622000121>
59. Jimmy B, Jose J. Patient Medication Adherence: Measures in Daily Practice. *Oman Med J* [Internet]. Mei 2011;26(3):155–9. Tersedia pada: http://www.omjournal.org/fulltext_PDF.aspx?DetailsID=93&type=fulltext
60. Atkins L, Fallowfield L. Intentional and non-intentional non-adherence to medication amongst breast cancer patients. *Eur J Cancer* [Internet].

September 2006;42(14):2271–6. Tersedia pada:
<https://linkinghub.elsevier.com/retrieve/pii/S0959804906002097>

61. Irwin M. Theoretical Foundations of Adherence Behaviors. Clin J Oncol Nurs [Internet]. 1 Juni 2015;19(3):31–5. Tersedia pada:
<http://cjon.ons.org/cjon/19/3/supplement/theoretical-foundations-adherence-behaviors-synthesis-and-application-adherence>

